...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Gilead's GS-5829 flops in mCRPC
Reply New Message
Back To Forum List View
Icon president Gilead's GS-5829 flops in mCRPC
10
BearDownAZ
Jul 13, 2022 11:03AM
Icon president Re: Gilead's GS-5829 flops in mCRPC
5
Nextblockbuster
Jul 13, 2022 12:40PM
Re: Gilead's GS-5829 flops in mCRPC
2
tada
Jul 19, 2022 04:42PM

Tada, I believe GS-5829 (Alobresib) was developed in house by Gilead. I think you are are confusing this with Gilead's $21B purchase of Trodelvy, a breast cancer drug that Don was babbling on about a few presentations ago. 

4 Recommendations
Re: Gilead's GS-5829 flops in mCRPC
3
tada
Jul 20, 2022 09:26AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply